Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 12/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.40 |
| ▸ | GSK3B | P49841 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5118511 | 0.75 | MERTK (0.47) | ABCG2ABCB1GSK3BEGFRKDR | |
| SCHEMBL5120348 | 0.72 | KMT2A (0.40) | CA12CA1CA2CA9KDR | |
| SCHEMBL5110319 | 0.69 | NPSR1 (0.42) | KDRMAPTLMNATSHR | |
| SCHEMBL1880263 | 0.68 | ABCG2 (0.42) | ABCG2ABCB1EGFRKDRMAPT | |
| SCHEMBL15008705 | 0.67 | CA12 (0.44) | CA12CA1CA2CA9 | |
| SCHEMBL510240 | 0.66 | ALDH1A1 (0.62) | ABCG2ABCB1GSK3BEGFRKDR | |
| SCHEMBL9481712 | 0.66 | ALDH1A1 (0.62) | ABCG2ABCB1GSK3BEGFRKDR | |
| SCHEMBL395539 | 0.66 | CA2 (0.52) | ABCG2ABCB1CA12CA1CA2 | |
| SCHEMBL5111932 | 0.64 | AURKA (0.42) | GSK3BCA12CA1CA2CA9 | |
| SCHEMBL15008535 | 0.64 | CA12 (0.41) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234276-A1 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors | SENTINEL ONCOLOGY LIMITED (UK) | 2008-09-25 | — | — | US | claimed |
| US-20080234276-A1 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors | SENTINEL ONCOLOGY LIMITED (UK) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234276-A1 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors | HIF1AN, HIF1A, CDK2 | ABCG2 1813/4885ABCB1 2797/4885GSK3B 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.